PMG-1015 is under clinical development by Pulmongene and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMG-1015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PMG-1015 is under development for the treatment of idiopathic pulmonary fibrosis and unspecified indication. The therapeutic candidate is a monoclonal antibody. It is administered through intravenous route.
Pulmongene operates in the healthcare industry. Pulmongene is headquartered in Australia.
For a complete picture of PMG-1015’s drug-specific PTSR and LoA scores, buy the report here.